Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
SLDB Solid Biosciences	$6.08 -3.4%	$5.40	$2.41 ▼ $10.37	$470.95M	2.44	1.96 million shs	983,678 shs
SRPT Sarepta Therapeutics	$17.94 -1.6%	$21.73	$10.41 ▼ $144.22	$1.75B	0.46	6.06 million shs	11.07 million shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
SLDB Solid Biosciences	0.00%	-7.91%	+19.58%	+116.90%	-14.77%
SRPT Sarepta Therapeutics	0.00%	+14.58%	+0.33%	-49.88%	-85.46%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
SLDB Solid Biosciences	3.4122 of 5 stars	4.6	1.0	0.0	0.0	3.2	2.5	0.6
SRPT Sarepta Therapeutics	4.6071 of 5 stars	4.1	2.0	0.0	4.2	3.0	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
SLDB Solid Biosciences	3.17	Buy	$15.10	148.52% Upside
SRPT Sarepta Therapeutics	2.10	Hold	$44.17	146.19% Upside

Current Analyst Ratings Breakdown

Latest SLDB and SRPT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2025	SRPT Sarepta Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$19.00
8/7/2025	SRPT Sarepta Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$48.00 ➝ $50.00
7/29/2025	SRPT Sarepta Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underweight ➝ Equal Weight	$22.00
7/29/2025	SRPT Sarepta Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
7/29/2025	SRPT Sarepta Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Perform ➝ Market Perform	$25.00 ➝ $50.00
7/29/2025	SRPT Sarepta Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$15.00 ➝ $20.00
7/29/2025	SRPT Sarepta Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$15.00
7/29/2025	SRPT Sarepta Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell
7/29/2025	SRPT Sarepta Therapeutics	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Perform	$13.00
7/29/2025	SRPT Sarepta Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$30.00 ➝ $37.00
7/21/2025	SLDB Solid Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Overweight	$16.00

(Data available from 8/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
SLDB Solid Biosciences	$8.09M	58.21	N/A	N/A	$3.43 per share	1.77
SRPT Sarepta Therapeutics	$2.48B	0.71	$2.40 per share	7.48	$15.99 per share	1.12

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
SLDB Solid Biosciences	-$124.70M	-$2.99	N/A	N/A	N/A	N/A	-68.15%	-55.33%	8/12/2025 (Estimated)
SRPT Sarepta Therapeutics	$235.24M	-$0.87	N/A	1.64	N/A	-2.34%	-1.03%	-0.37%	N/A

Latest SLDB and SRPT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	SLDB Solid Biosciences	-$0.51	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	SRPT Sarepta Therapeutics	$0.89	$2.02	+$1.13	$1.89	$530.66 million	$611.09 million
5/15/2025	Q1 2025	SLDB Solid Biosciences	-$0.53	-$0.59	-$0.06	-$0.59	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
SLDB Solid Biosciences	N/A	N/A	N/A	N/A	N/A
SRPT Sarepta Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
SLDB Solid Biosciences	N/A	10.89	10.89
SRPT Sarepta Therapeutics	0.84	2.89	1.81

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
SLDB Solid Biosciences	81.46%
SRPT Sarepta Therapeutics	86.68%

Insider Ownership

Company	Insider Ownership
SLDB Solid Biosciences	13.63%
SRPT Sarepta Therapeutics	7.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
SLDB Solid Biosciences	100	77.51 million	66.95 million	Optionable
SRPT Sarepta Therapeutics	1,372	97.71 million	90.29 million	Optionable

SLDB and SRPT Headlines

Recent News About These Companies

Sarepta Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights – SRPT

2 hours ago | globenewswire.com

Sarepta Therapeutics (SRPT) Declines Again On EMA Recommendation to Refuse ELEVIDYS Marketing Authorization, Securities Class Action Pending – Hagens Berman

2 hours ago | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT

August 11 at 10:00 AM | prnewswire.com

SRPT LAWSUIT ALERT: The Gross Law Firm Notifies Sarepta Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

August 11 at 8:45 AM | prnewswire.com

SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group Before the Final Deadline - SRPT

August 11 at 8:41 AM | prnewswire.com

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. (NASDAQ: SRPT)

August 11 at 8:30 AM | globenewswire.com

SRPT COURT NOTICE: Sarepta Therapeutics Investors may have been Affected by Fraud -- Contact BFA Law before August 25 if You Suffered Losses (NASDAQ:SRPT)

August 11 at 8:18 AM | globenewswire.com

Mizuho Markets Americas LLC Sells 178,451 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

August 11 at 7:57 AM | marketbeat.com

SRPT Lawsuit Alert! Class Action Lawsuit Against Sarepta Therapeutics

August 11 at 7:39 AM | tipranks.com

These Stocks Are Moving the Most Today: Coinbase, MicroStrategy, Sarepta, Nvidia, AMD, and More

August 11 at 5:26 AM | barrons.com

SRPT DEADLINE ALERT: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – SRPT

August 10 at 8:24 AM | globenewswire.com

Sarepta Therapeutics (SRPT) Receives a Sell from Citi

August 10 at 8:21 AM | theglobeandmail.com

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by MUFG Securities EMEA plc

August 10 at 6:36 AM | marketbeat.com

Sarepta Therapeutics (NASDAQ:SRPT) Upgraded to "Hold" at Wall Street Zen

August 10 at 3:32 AM | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT

August 9 at 10:43 AM | globenewswire.com

SRPT NEWS: Did Sarepta Therapeutics Mislead Investors? Contact BFA Law by August 25 Class Action Deadline (NASDAQ:SRPT)

August 9 at 7:36 AM | globenewswire.com

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by New Age Alpha Advisors LLC

August 9 at 4:27 AM | marketbeat.com

SRPT INVESTOR NOTICE: Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit

August 8 at 9:40 PM | prnewswire.com

BMO Capital Reaffirms Their Hold Rating on Sarepta Therapeutics (SRPT)

August 8 at 8:03 PM | theglobeandmail.com

Shareholders that lost money on Sarepta Therapeutics, Inc.(SRPT) should contact Levi & Korsinsky about pending Class Action - SRPT

August 8 at 4:04 PM | globenewswire.com

SRPT Deadline: SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit

August 8 at 3:22 PM | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLDB and SRPT Company Descriptions

Solid Biosciences NASDAQ:SLDB

$6.08 -0.21 (-3.40%)

Closing price 03:59 PM Eastern

Extended Trading

$6.08 0.00 (-0.02%)

As of 05:33 PM Eastern

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

Sarepta Therapeutics NASDAQ:SRPT

$17.94 -0.29 (-1.59%)

Closing price 04:00 PM Eastern

Extended Trading

$17.90 -0.05 (-0.25%)

As of 05:38 PM Eastern

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time